Core Insights - Cencora (COR) is expected to report its third-quarter fiscal 2025 results on August 6, with a history of earnings surprises, averaging 6% over the last four quarters [1][2] Revenue and Earnings Estimates - The Zacks Consensus Estimate for Cencora's revenues is $80.33 billion, reflecting an 8.2% increase from the same quarter last year [2] - The consensus estimate for earnings is $3.78 per share, indicating a 13.2% improvement year-over-year [2] Segment Performance - The U.S. Healthcare Solutions segment is driving growth, with revenues of $68.3 billion in the second quarter, an 11% year-over-year increase, supported by strong demand for specialty medicines [3][4] - Specialty products are a key growth area, with operating income in the U.S. segment rising 23% in the fiscal second quarter, despite a 10% sequential decline in GLP-1 revenue due to seasonal factors [4][10] - The International Healthcare Solutions segment showed modest performance, generating $7.2 billion in revenue last quarter, with a 1% increase reported and a 17% decline in operating income [6][10] Strategic Developments - Cencora's acquisition of Retina Consultants of America (RCA) is expected to enhance the company's margin profile, with RCA's impact becoming more visible as integration progresses [7] - The company has raised its full-year operating income outlook for the U.S. Healthcare Solutions segment, anticipating continued benefits from strong first-half performance [3] Earnings Outlook - The model does not predict an earnings beat for Cencora this quarter, with an Earnings ESP of 0.00% [11]